Clinical trial · Observational
Pathological Response After Neoadjuvant Treatment on NSCLC
Retrospective Observational Study of Resectable Stage IIIA Non-small Cell Lung Cancer Patients: Pathological Response After Neoadjuvant Treatment and Patient Outcomes
NCT05167487CI-TRIAL-00102616PLANETrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a non-interventional, observational, multicenter and retrospective study. Being limited to the collection of patient data already filled in the Tumor Thoracic Registry data base and the data from stage IIIA clinical trials case report forms.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stage IIIA Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin | Drug | Carboplatin | ALIAS |
| Cisplatin | Drug | Cisplatin | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Experimental: platinum-based neoadjuvant treatment and surgery.
- description
- Resectable stage IIIA non-small cell lung cancer patients treated with platinum-based neoadjuvant treatment and surgery.
- interventionNames
- Drug: Cisplatin
- Drug: Carboplatin
Primary outcomes (1)
- measure
- To assess pathological response after neoadjuvant treatment as a subrogate endpoint for overall survival and disease-free survival in resectable stage IIIA non-small cell lung cancer patients.
- timeFrame
- From the end of neoadjuvant treatment until the last follow up or death, assessed up to 45 months
- description
- Pathological response will be assessed as complete pathological response, major pathological response (defined as ≤10% of viable tumor cells) and incomplete pathological response.
Secondary outcomes (4)
- measure
- To describe the percentage of residual viable tumor in this population of patients under common criteria
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with resectable stage IIIA disease (according to American Joint Committee on Cancer \[AJCC\] lung cancer edition 7 or 8) who were included in the Tumor Thoracic Registry data base and in stage IIIA clinical trials which the sponsor is Fundación GECP. * Patients with histologically N2 involvement confirmed * Patients diagnosed as stage IIIA from 2010 and 2017 * Patients who have received neoadjuvant platinum-based treatment and surgery * Age ≥ 18 years at time of study entry * PET /TC at diagnosis Exclusion Criteria: * Patients who received chemoradiotherapy neoadjuvant treatment * Patients who were not resected after neoadjuvant treatment * Patients who were diagnosed after June 2017
References
Publications (0)
Data not yet available
No reference posted for this study.